{"filings":[{"id":1749596,"accession_number":"0001193125-26-309012","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-07-20T20:44:31+00:00","items":["1.03","3.01"],"status":"ready","headline":"Sangamo Therapeutics receives Nasdaq delisting denial; bankruptcy court approves asset sale bidding procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bankruptcy court approved asset sale bidding procedures; bid deadline Aug 4, auction Aug 10, sale hearing Aug 20.","Nasdaq Hearings Panel denied listing continuation; company will not appeal; expects Form 25 delisting.","Stock suspended from Nasdaq since May 5, 2026; currently trades on OTCQB under symbol SGMOQ.","Company filed Chapter 11 on June 23, 2026; continues as debtor-in-possession under court jurisdiction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-20","daily_digest_url":"/daily/2026-07-20","daily_digest_rank":10},{"id":1387518,"accession_number":"0001193125-26-292501","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-07-01T20:01:16+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Sangamo Therapeutics files Chapter 11; stock now trades on OTCID Basic under SGMOQ; auditor EY terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed voluntary Chapter 11 petition (Case No. 26-10989) on June 24, 2026.","Common stock began trading on OTCID Basic Market under symbol SGMOQ on June 24, 2026.","Nasdaq delisting appeal pending; stock suspended from Nasdaq since May 5, 2026.","Audit committee terminated Ernst & Young as independent auditor on June 25, 2026.","No new auditor engaged; EY's reports included going-concern explanatory paragraph."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1223517,"accession_number":"0001193125-26-279630","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K/A","filed_at":"2026-06-23T20:42:16+00:00","items":["9.01"],"status":"ready","headline":"Sangamo files Ch 11, sells key capsid/gene therapy assets to Eli Lilly and Astellas","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sangamo filed Chapter 11 bankruptcy and signed asset sale agreements with Eli Lilly and Astellas Gene Therapies.","Lilly's subsidiary is stalking horse bidder for capsids (STAC-150, STAC-BBB), SIFTER, MINT, and zinc finger prion assets.","Astellas acquires assets under separate agreement; terms not disclosed in this filing.","Sangamo common stock delisted from Nasdaq on May 5, 2026; now trading on OTCQB.","Sale subject to Bankruptcy Court approval and potential higher bids in auction process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1204918,"accession_number":"0001193125-26-278582","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-06-23T12:45:37+00:00","items":["1.01","1.03","2.03","2.05"],"status":"ready","headline":"Sangamo Therapeutics files for Chapter 11 bankruptcy; enters stalking horse asset sales to Lilly and Astellas","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed voluntary Chapter 11 petition on June 23, 2026; stock suspended from Nasdaq on May 5, 2026, now trades on OTCQB.","Entered stalking horse APA with Lilly for $50M to sell technology platforms including STAC-BBB, zinc finger, Modular Integrase, and prion program.","Entered stalking horse APA with Astellas for $25M upfront plus up to $25M milestones for Fabry disease candidate isaralgagene civaparvovec.","Obtained $30M DIP financing commitment from Northridge ATM, LLC to fund post-petition operations, subject to court approval.","Board approved restructuring eliminating ~51 roles (~40% of workforce); expects $3-4M severance costs; retaining 77 employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442359,"accession_number":"0001628280-26-035061","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-05-14T20:02:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.","Cash and cash equivalents $27.6M as of March 31 – expects to fund operations only into Q3 2026.","Common stock delisted from Nasdaq, now trading on OTCQB; hearing to appeal delisting scheduled June 9.","Rolling BLA for Fabry gene therapy ST-920 underway; CMC module completion expected summer 2026 subject to funding.","2026 GAAP operating expense guidance $110M-$130M; company warns guidance depends on securing additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":1442000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90498,"accession_number":"0001628280-26-028128","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.","Trading will be suspended at open on May 5, 2026; company plans to appeal before Nasdaq Hearings Panel.","Common stock approved for quotation on OTCQB Venture Market starting May 5, 2026 under symbol SGMO.","Company previously received two compliance periods but remained non-compliant with bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100055,"accession_number":"0001628280-26-022006","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).","Revenue in 2025 fell to $39.6M from $57.8M; Q4 revenue $14.2M up from $7.6M, driven by Pfizer and Lilly collaborations.","Cash and equivalents $20.9M as of Dec 31; expects funding into Q3 2026 after recent $25M offering and other receipts.","Rolling BLA submission to FDA for ST-920 (Fabry gene therapy) in progress; CMC module expected summer 2026 subject to funding.","Neurology pipeline advancing: Phase 1/2 STAND study for ST-503 in chronic pain with six sites activated; Eli Lilly capsid license added."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100054,"accession_number":"0001193125-26-036792","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.","Combined price per share+ warrant is $0.4719; pre-funded warrant+ warrant at $0.4619; gross proceeds ~$25M.","Existing warrants held by investor repriced from $1.00 to $0.4719 and expiration extended to 5.5 years from closing.","Closing expected February 4, 2026; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100053,"accession_number":"0001001233-26-000005","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.","Positive mean annualized eGFR slope of 1.965 at Week 52 (95% CI -0.153, 4.083) across 32 patients; Week 104 slope 1.747.","All 15 ERT-naïve patients achieved normal/supraphysiological α-Gal A activity up to 54 months; 18 ERT patients safely withdrew from ERT.","32 of 33 patients completed 52-week follow-up; ST-920 well-tolerated with no discontinuations due to AEs, no TMA or complement activation.","Statistically significant improvements in SF-36 QoL and GSRS diarrhea scores at Week 52; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100052,"accession_number":"0001001233-26-000002","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","5.02"],"status":"ready","headline":"Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).","CFO Prathyusha Duraibabu's employment terminated effective Feb 2, 2026.","Nikunj Jain (VP Finance, Controller) appointed Interim CFO effective Feb 3, 2026; no additional compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116397,"accession_number":"0001001233-25-000023","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.","Revenue of $0.6M down from $49.4M, mainly due to absence of Genentech collaboration revenue.","Cash and equivalents $29.6M; with Pfizer $6M license fee and ATM proceeds, runway into Q1 2026.","FDA reiterated eGFR slope endpoint for isaralgagene civaparvovec accelerated approval; BLA submission expected as early as Q1 2026.","First two clinical sites activated for Phase 1/2 ST-503 chronic neuropathic pain study; first patient dosing expected in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":25324000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116396,"accession_number":"0001001233-25-000015","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sangamo gets Nasdaq extension to April 27, 2026 to meet $1.00 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension from Nasdaq until April 27, 2026 to regain minimum bid price compliance.","Must close at $1.00+ for 10 consecutive trading days to cure deficiency.","Original non-compliance notice was dated April 30, 2025; first cure deadline was Oct 27, 2025.","Failure to cure by April 27, 2026 will trigger delisting notice; company may appeal.","No assurance of regaining compliance; shares continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132848,"accession_number":"0001001233-25-000013","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sangamo CFO Duraibabu resigns effective Oct 1, stays part-time; Jain new principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Duraibabu resigns effective Oct 1, 2025; transitions to part-time principal financial officer role.","Nikunj Jain, VP Finance & Corporate Controller since 2021, appointed principal accounting officer.","Jain's agreement: annual base salary $347,548; target annual cash bonus 30% of base; eligible for equity awards.","Duraibabu's part-time agreement: base salary $145,188; $160,000 retention bonus payable Jan 31, 2026.","Duraibabu severance limited to change of control; no other severance under plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132847,"accession_number":"0001001233-25-000011","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.","She will transition to part-time employment and remain interim principal financial officer until a successor is appointed.","Company thanks Duraibabu for contributions to strategic collaborations and investment allocations positioning Sangamo as a neurology-focused genomic medicines company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132846,"accession_number":"0001001233-25-000006","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.","All 18 patients on ERT at baseline safely withdrew; one later resumed per physician's decision.","69% of patients improved FOS-MSSI severity score at 12 months; SF-36 QoL scores showed statistically significant gains.","BLA submission for isaralgagene civaparvovec targeted Q1 2026 under Accelerated Approval pathway, subject to funding.","Company notes need for substantial additional capital to continue as going concern and advance Fabry program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132845,"accession_number":"0001628280-25-038855","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.","BLA submission for isaralgagene civaparvovec expected as early as Q1 2026; business development for Fabry commercialization ongoing.","First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain; first patient dosing expected fall 2025, preliminary efficacy data Q4 2026.","Q2 2025 revenue $18.3M (vs $0.3M YoY) driven by Lilly license payment; net loss $20.0M ($0.08 EPS) vs $36.1M ($0.18 EPS) prior year.","Cash $38.3M as of June 30; raised ~$21M net from equity offering; expects funding into Q4 2025; reaffirms 2025 opex guidance $135-155M GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":24743000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149400,"accession_number":"0001628280-25-032748","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.","All 18 patients on ERT at baseline withdrawn from ERT and remain off; α-Gal A activity sustained up to 4.5 years.","Reported eGFR slope compares favorably to Replagal (-2.2), Fabrazyme (-1.5), Galafold (-0.4) in published studies.","Significant SF-36 quality-of-life improvements: role-physical +14.8, vitality +9.6, bodily pain +9.0 at week 52.","No preconditioning required; most adverse events grade 1-2; no safety-related discontinuations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149399,"accession_number":"0001628280-25-031559","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sangamo stockholders approve 14M share increase to 2018 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share reserve increased by 14,000,000 shares; total now includes 8.8M, 9.9M, 7.9M, 10M, 11M from prior years.","Incentive stock option limit raised to 123,200,000 shares.","All nine director nominees elected, including Courtney Beers, Kenneth Hillan, and H. Stewart Parker.","Advisory say-on-pay approved: 32.8M for, 23.2M against, 1.3M abstentions.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 119.6M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149398,"accession_number":"0001140361-25-018697","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo Therapeutics raises ~$23M in underwritten public offering of common stock and warrants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Offering of 12.2M shares and pre-funded warrants for 34.4M shares, each with accompanying purchase warrant, at $0.50 unit price.","Gross proceeds expected ~$23M, before underwriting discounts and expenses; closing expected May 14, 2025.","Pre-funded warrants exercisable at $0.01 per share; purchase warrants at $0.75 per share, exercisable after six months for six years.","Sangamo may force exercise of purchase warrants if stock price exceeds $2.75 for ten consecutive trading days after six months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149397,"accession_number":"0001628280-25-022664","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sangamo receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 30, 2025, Nasdaq notified Sangamo that its stock closed below $1.00 for 30 consecutive business days.","Company has until October 27, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may qualify for a second 180-day period if other listing standards are met.","Failure to cure could result in delisting from the Nasdaq Capital Market.","Sangamo will monitor bid price and evaluate options including a reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168461,"accession_number":"0001628280-25-013085","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.","Cash $41.9M at Dec 31, 2024; with $10.1M ATM proceeds and $5M Pfizer payment, funds operations into mid-Q2 2025.","FDA cleared IND for ST-503 (chronic neuropathic pain); patient enrollment expected mid-2025; preliminary efficacy data Q4 2026.","FDA agreed to Accelerated Approval for isaralgagene civaparvovec in Fabry using Phase 1/2 data; BLA submission H2 2025.","License agreements with Genentech (Aug 2024) and Astellas (Dec 2024) for STAC-BBB capsid; $20M upfront from Astellas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168460,"accession_number":"0001628280-25-004197","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo reports updated Phase 1/2 STAAR data for ST-920; eGFR slope +3.061; FDA Accelerated Approval path confirmed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.","ERT-naïve/pseudo-naïve patients showed sustained α-Gal A activity up to 42 months; 17/18 ERT patients remain off ERT.","23 patients with ≥12 months follow-up: mean annualized eGFR slope +3.061 (95% CI 0.863-5.258), indicating potential kidney improvement.","FDA agreed to Accelerated Approval using 52-week eGFR slope; BLA submission expected H2 2025.","Significant QoL (SF-36 General Health +10.6, p=0.0020) and GI symptom improvements; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185594,"accession_number":"0001628280-24-052579","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.","Sangamo forfeits up to $220M in remaining milestones and all future royalties (14-20% of net sales).","Sangamo receives exclusive license back to develop and commercialize SB-525; Pfizer gets low single digit royalties.","Sangamo plans to seek a new partner to advance regulatory filings for giroctocogene fitelparvovec.","Pfizer had paid $125M already ($70M upfront + $55M milestones); remaining program rights revert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185593,"accession_number":"0001628280-24-050545","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).","84% of participants (42/50) achieved FVIII activity >5% at Month 15; 88% had no treated bleeds.","Safety: no FVIII inhibitors, no treatment-related malignancies; ALT elevations manageable with corticosteroids.","Delaware Court validated share increase vote standard; Sangamo dismissed Section 205 application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185592,"accession_number":"0001628280-24-047099","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo posts Q3 net income $10.7M; FDA clears Accelerated Approval path for Fabry gene therapy ST-920","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.","Revenue $49.4M (up from $9.4M), driven by $49.2M from Genentech collaboration.","FDA agrees Phase 1/2 STAAR data can support Accelerated Approval for ST-920 in Fabry disease; BLA submission expected H2 2025.","Received $50M from Genentech upfront/milestones; eligible for up to $1.9B in additional milestones plus tiered royalties.","Cash $39.2M; expects to fund operations into Q1 2025 including $10M milestone from Genentech."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":50249000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185591,"accession_number":"0001628280-24-042308","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sangamo files to validate share increase; stockholder challenge; hearing Dec 12","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Stockholder lawsuit claims wrong voting standard for share increase; company seeks validation.","Sangamo filed Section 205 petition to validate amendment increasing authorized shares from 640M to 960M.","Vote results: 107.95M for (52% of outstanding, 92% of votes cast); both standards met.","Court of Chancery hearing scheduled Dec 12, 2024; opposition due Nov 12.","Company previously warned of going concern risk; validation needed to enable equity fundraising."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202171,"accession_number":"0001628280-24-035160","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.","Q2 net loss $36.1M ($0.18/sh) vs $114.5M ($0.66); revenue $0.3M down from $6.8M.","Cash $27.8M at June 30; with Genentech $50M, runway into Q1 2025.","Pfizer's Phase 3 hemophilia A gene therapy met primary endpoint; Sangamo eligible for up to $220M milestones and 14-20% royalties.","Fabry disease: 33 patients dosed, 17 off ERT; eGFR improvement observed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":837000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202170,"accession_number":"0001628280-24-032815","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.","84% of participants maintained FVIII activity >5% at 15 months; mean treated ABR reduced 98.3% (0.07 vs 4.08, p<0.0001).","Sangamo eligible for up to $220M in regulatory/commercial milestones plus 14%-20% royalties on sales.","One participant (1.3%) returned to prophylaxis; treatment generally well tolerated with transient elevated FVIII in 49.3%.","Pfizer to discuss data with regulatory authorities; Sangamo's first potential commercial medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218228,"accession_number":"0001628280-24-026903","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Sangamo shareholders approve increase in authorized shares and equity plan share reserve at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock increased from 640M to 960M shares (320M increase).","2018 Equity Incentive Plan amended to add 11M shares to the reserve (total available now ~49.3M plus returning shares).","All nine director nominees elected; advisory 'say-on-pay' passed with 101.3M votes for vs 15.1M against.","Ratification of Ernst & Young as independent auditor for FY2024 approved with 151.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218227,"accession_number":"0001628280-24-022186","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.","Revenue fell to $0.5M from $158M, driven by termination of Biogen/Novartis collaborations.","Cash $54.4M at March 31 (down from $81M); raised ~$24M gross via direct offering.","Pfizer expects BLA/MAA submission for hemophilia A gene therapy in early 2025 if mid-2024 pivotal readout positive.","Fabry gene therapy STAAR study fully dosed; seeking collaboration partner before registrational trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":481000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218226,"accession_number":"0001628280-24-019337","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sangamo receives Nasdaq deficiency notice for bid price below $1 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received April 24, 2024; stock closed below $1 for 30 consecutive business days.","Company has 180 calendar days until October 21, 2024 to regain compliance.","If not compliant, may transfer to Nasdaq Capital Market for an additional 180-day period.","Evaluating options including a potential reverse stock split to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238195,"accession_number":"0001193125-24-076613","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.","Gross proceeds expected ~$24.0M; closing on or about March 26, 2024.","Placement agents: Barclays Capital Inc. and Cantor Fitzgerald & Co.; 6% cash fee.","Pre-funded warrant exercise price $0.01; purchase warrant exercise price $1.00 with 5.5-year term.","Lock-Up Agreements from directors and officers restrict share sales for a period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238194,"accession_number":"0001628280-24-010790","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo reports $257.8M net loss for FY2023; cash runway into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $257.8M ($1.48/share) on revenue $176.2M (up 58% YoY on Biogen termination).","Cash $81.0M as of Dec 31, 2023; expects funding into Q3 2024 without additional capital.","STAC-BBB capsid showed 700-fold higher brain transduction vs AAV9 in NHPs; pain IND Q4 2024.","Fabry drug aligned with FDA on abbreviated approval pathway; EMA PRIME granted; seeking partner.","Wind down of French ops (93 roles); 2024 GAAP opex guidance $145–165M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238193,"accession_number":"0001628280-24-003506","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo: ST-920 gene therapy shows sustained efficacy; defers Phase 3 pending partnership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Sep 19, 2023 cutoff, 24 patients dosed; all 12 withdrawn from ERT remain off ERT with sustained supraphysiological α-Gal A activity.","In dose escalation phase, all 9 patients had sustained elevated α-Gal A activity for nearly 3 years; 5 ERT patients completed withdrawal.","At highest dose (2.63×10^13 vg/kg), ERT-naïve patients showed supraphysiological α-Gal A up to ~500 days with lyso-Gb3 reduction/stabilization.","Mean annualized eGFR slope -0.915 mL/min/1.73m²/yr; 69% improved total FOS-MSSI; statistically significant SF-36 and GSRS improvements.","Company defers further investment in registrational trial planning until collaboration partnership or financing is secured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238192,"accession_number":"0001628280-24-001784","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sangamo Therapeutics eliminates 2023 executive bonuses, adopts retention program amid capital raise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined not to award 2023 annual cash bonus to CEO Sandy Macrae or CFO Prathyusha Duraibabu.","Retention program approved for US/UK employees; CEO eligible for up to $429,820, CFO up to $193,584.","Retention payments conditioned on achieving capital-raising milestones by end of 2024 or change of control.","Executives must remain employed through payment date; program highlights company's cash needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255659,"accession_number":"0001628280-23-041394","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo/Pfizer Alta study: 4-year data shows mean ABR 1.4, sustained FVIII activity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 4 (3e13 vg/kg) mean ABR 1.4, median 0.0; 3 of 5 participants had zero bleeds post-infusion.","FVIII activity maintained in mild-to-normal range in 4 of 5 participants over 4-year follow-up; 1 participant had FVIII BLOQ.","No new safety signals; no thrombotic, neoplastic events, or FVIII inhibitors; LFT elevations resolved with steroids.","Pfizer expects pivotal Phase 3 AFFINE readout mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255658,"accession_number":"0001628280-23-036697","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo reports updated Phase 1/2 Alta data for hemophilia A gene therapy; FVIII maintained through ~4 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single infusion of giroctocogene fitelparvovec (3e13 vg/kg) maintains FVIII activity in mild-to-normal range through up to 208 weeks.","Mean annualized bleeding rate in high-dose cohort was 0 in year 1 and 1.2 overall; no participants resumed prophylaxis.","No confirmed FVIII inhibitor development, no thrombotic events, and liver safety resolved without sequelae.","Pfizer expects pivotal Phase 3 AFFINE trial readout in mid-2024.","Updated data to be presented at ASH Annual Meeting on December 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255657,"accession_number":"0001628280-23-035948","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo reports Q3 net loss $104.2M, cuts 40% of workforce, focuses on neurology","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $104.2M ($0.59/share) vs $53.2M ($0.34) year ago; revenue $9.4M down from $26.5M.","Workforce reduction ~40% (~162 roles); Brisbane HQ to close early 2024; headquarters move to Richmond, CA.","COO Mark McClung and CSO Jason Fontenot leaving Jan 2, 2024; Amy Pooler and Gregory Davis appointed heads of Research and Technology.","Cash $132.1M at Sep 30, 2023; expects runway into Q3 2024; non-GAAP opex 2024 ~$115-135M (down ~50%).","Deferring new investments in Fabry and CAR-Treg programs; seeking partners/investors; Fabry Phase 1/2 data update expected early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":174190000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273098,"accession_number":"0001628280-23-028183","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo Q2 net loss $114.5M, revenue down 77% YoY; impairments of $51.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $114.5M ($0.66/sh) vs $43.2M ($0.29/sh) YoY, driven by $51.3M intangible asset impairment.","Revenue $6.8M vs $29.4M YoY, down 77% due to terminations of Novartis, Biogen, Sanofi deals.","Total GAAP op expenses $130.4M (incl. $51.3M impairment); non-GAAP op expenses $72.3M.","Cash & marketable securities $182.1M at June 30; raised $15.1M via ATM; cash runway >12 months.","Updated 2023 GAAP op expense guidance $378-398M; non-GAAP unchanged at $240-260M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":164792000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289948,"accession_number":"0001628280-23-020692","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Sangamo shareholders approve doubling authorized common stock to 640M and 10M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 320M to 640M shares; filings made June 2, 2023.","2018 Equity Incentive Plan amended to add 10M shares; max incentive stock options raised to 73.2M shares.","Amendment adopted to limit officer monetary liability for breach of fiduciary duty under Delaware law.","All nine director nominees elected; advisory Say-on-Pay approved with 87.4% of votes cast For.","Advisory vote on executive compensation frequency set to every year going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289947,"accession_number":"0001628280-23-013290","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Sangamo cuts 27% of US workforce, restructures toward neurology and Fabry; EVP departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["US workforce reduced by ~120 roles (~27%); expects ~$31M annualized cost savings from restructuring.","EVP Technical Operations R. Andrew Ramelmeier to leave July 10, 2023; Phillip Ramsey appointed Head of Technical Ops.","Preliminary Q1 cash position expected to fund operations for at least 12 months; full Q1 results due by May 10, 2023.","Strategic focus on Nav1.7 (IND 2024), prion (IND 2025), Fabry Phase 3 trial, and TX200 CAR-Treg; pauses partnered programs.","One-time restructuring costs estimated at $5M-$7M, primarily in Q2 2023; reduces internal manufacturing and allogeneic footprints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310913,"accession_number":"0001628280-23-008516","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Sangamo announces termination of Novartis and Biogen collaborations; loses milestone/royalty potential","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novartis terminated collaboration (effective June 11, 2023); Sangamo loses up to $720M in milestones and royalties.","Biogen terminated collaboration (effective June 15, 2023); Sangamo loses up to $2.37B in milestones and royalties.","Sangamo will explore internal development or new partners for CNS programs but faces uncertainty.","Company expects existing cash runway of at least 12 months from Dec. 31, 2022 remains adequate despite terminations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310912,"accession_number":"0001628280-23-007777","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo recovers $34.4M in SVB deposits; funds moved to alternative banks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Had approximately $34.4M in deposits with Silicon Valley Bank, substantially all uninsured.","FDIC transferred all deposits to a bridge bank on March 13; Sangamo accessed full amount.","Substantially all deposits transferred to alternative global banking providers on March 13.","Expects to migrate all banking services from SVB to alternative global banking providers.","No loss of funds; cash position unaffected by SVB closure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310911,"accession_number":"0001628280-23-007587","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo has $34.4M in uninsured deposits at failed Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sangamo had approximately $34.4 million in deposits with SVB as of March 10, 2023, substantially all uninsured.","Total cash, cash equivalents, and marketable securities were $307.5 million as of December 31, 2022.","FDIC stated uninsured depositors will receive an advance dividend within one week; full recovery timing and amount unknown.","Company expects to meet payroll and supplier obligations through other banking providers despite SVB failure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310910,"accession_number":"0001628280-23-006626","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo Therapeutics files prospectus supplement for up to $204M in ATM sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Remaining ATM capacity of $204.1M under $325M Sales Agreement with Jefferies LLC as of March 7, 2023.","Filed Amendment No. 3 to the Open Market Sale Agreement to reflect the remaining shares.","Filed legal opinion from Cooley LLP on validity of the common stock offered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310909,"accession_number":"0001628280-23-006092","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sangamo Therapeutics decides not to proceed with public offering; reaffirms cash runway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sangamo explored a potential public offering but chose not to move forward after evaluating market conditions and business outlook.","Company believes available cash, equivalents, and marketable securities will fund operations for at least 12 months from Dec 31, 2022 10-K.","Sangamo will continue to seek additional capital, including non-dilutive sources, and may pursue equity financing in the future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310908,"accession_number":"0001628280-23-004552","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo reports Q4 net loss $52M, cash down to $307.5M; halts sickle cell investment, seeks partner","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $52.0M ($0.32/share) vs $37.5M loss in Q4 2021.","Full year 2022 net loss $192.3M ($1.25/share) vs $178.3M in 2021.","Cash and marketable securities $307.5M at Dec 31, 2022, down from $464.7M a year ago.","2023 GAAP operating expense guidance $310-330M; non-GAAP $275-295M.","Discontinuing material investments in sickle cell program; seeking collaboration partner for Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":111299000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329519,"accession_number":"0001628280-22-032552","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sangamo Therapeutics expands ATM equity offering capacity by $175M to $325M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 with Jefferies LLC adds $175M in common stock to existing at-the-market program.","Prior to amendment, $115M of original $150M capacity had been sold.","Remaining capacity under amended agreement is approximately $210M (based on $325M total less $115M sold).","Terms and conditions of the Sales Agreement unchanged; shares sold at market prices under effective shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329518,"accession_number":"0001628280-22-032209","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Sangamo appoints Courtney Beers and Margaret Horn to board; grants equity awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Courtney Beers (Ph.D.) and Margaret A. Horn appointed to board effective Dec 15, 2022; Dr. Beers joins Compensation Committee, Ms. Horn joins Nominating Committee.","Each received automatic grant: option to purchase 37,500 shares at $3.30 (Dec 15 closing price) vesting over 36 months, and RSU of 18,750 shares vesting in 3 annual installments.","Board approved Fifth Amended and Restated Bylaws; includes updates for universal proxy rules (Rule 14a-19), Delaware exclusive forum, and stockholder proposal procedures.","Standard indemnification agreements entered with each new director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329517,"accession_number":"0001628280-22-031695","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo Therapeutics presents updated proof-of-concept data for BIVV003 and giroctocogene fitelparvovec at ASH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BIVV003 in sickle cell disease: 3 of 4 Group 1 patients maintained HbF >30% with no severe VOCs up to 30 months.","Group 2 Patient 5 achieved HbF 45% and total Hb 12.4 g/dL at week 26 using improved manufacturing.","Hemophilia A gene therapy: highest dose cohort had zero annualized bleeding rate in first year post-infusion.","Mean FVIII activity at week 156 was 25.5% of normal in highest dose cohort with no inhibitor development.","No treatment-related serious adverse events for BIVV003; one grade 3 hypotension event in hemophilia A study resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-12T23:59:59+00:00|329517"}